ESMO Adds Daraxonrasib to 2nd-Line Metastatic Pancreatic Cancer Guidelines

2 articles · Updated · Oncodaily · Aug 21

ESMO issued an Express Guideline Update recommending daraxonrasib for second-line treatment of metastatic pancreatic cancer.
The update centers on RAS inhibition in pancreatic cancer, a treatment approach highlighted by ESMO Chief Medical Officer George Pentheroudakis in announcing the change.
The revised recommendation updates ESMO’s Clinical Practice Guidelines for pancreatic cancer, signaling a new standard reference point for oncologists treating metastatic disease.

Sources

With survival rates doubling, will the FDA fast-track daraxonrasib's approval for metastatic pancreatic cancer before the year ends?

Could a new genetic profiling mandate be the key to unlocking a 60 percent drop in pancreatic cancer mortality?